Yasunori Aizawa
Chief Scientific Officer Logomix,Inc.
Seminars
Thursday 10th September 2026
Engineering Next-Generation Ipscs via Precise Genome Rewriting for Scalable T1d Cell Therapy
12:00 pm
- High‑Throughput iPSC Screening: Leveraged GenoWriting™ to construct and screen a complete loss‑offunction iPSC library without residual gene expression.
- Enhanced Beta Cell Yields: Identified a double‑KO line that significantly boosted pancreatic beta cell differentiation efficiency.
- Rapid In Vivo Blood Glucose Control: Transplanting double‑KO cells into diabetic mice accelerated normoglycemia, improving T1D therapy scalability
